|
|
Post by kc on May 30, 2015 11:18:04 GMT -5
I guess that Sanofi has finally got the Pfizer plant up and running in Germany. Chancellor Merkel dedicated it on 5/28/2015. I wonder how many lines of Afrezza the plant is capable of handling? Will this be for lines 4,5,6 ? I am sure there is an advantage to have they lines in the same factory that is producing the insulin. The equipment to produce Afrezza is also German equipment (I believe). It would be very nice to learn that Sanofi has ordered equipment for the plant for delivery in 12 - 18 months. I remember reading that the lead time for the equipment is 12 months? Does anybody know this for sure?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 30, 2015 14:10:47 GMT -5
KC, I believe Al stated that it takes 6-9 months from the time the capital equipment is ordered until it is producing salable product. Back out shipping time to US (2-4 weeks including customs etc?). I read the article which mentioned insulin. How do you know it is for Afrezza?
|
|
|
|
Post by liane on May 30, 2015 14:38:52 GMT -5
We don't know it's for Afrezza. In fact it would make no sense at this point. Afrezza not yet approved in EU - and that is something like a year long process. Now if tomorrow there was a PR that Sanofi had filed, then I could see them starting to get a plant on line.
|
|
|
|
Post by kc on May 30, 2015 15:13:57 GMT -5
The article might be poorly worded but its still vague on what they mean by New Insulin Therapy. That may only be Toujeo. But its nice to see they plan on investing another 100 million Euro's in equipment at the plant. 
hugin.info/152918/R/1924322/690231.pdf
German Chancellor discussed fostering antibiotics research and inaugurated new high-tech manufacturing facility -
Paris and Frankfurt - May 28, 2015 - German Chancellor Dr. Angela Merkel met with Sanofi Chief Executive Officer Dr. Olivier Brandicourt, Boris Rhein, Hesse's Minister for Science and the Arts, leaders of the Fraunhofer Society and researchers from Sanofi to discuss the current status of antibiotics research and to gather ideas for encouraging and fostering additional antibiotics research initiatives.
The emerging concern about antibiotic resistance has led to calls by elected officials and global health leaders to invest in developing new antibiotic therapies. In fact, the G7 Summit, hosted by Chancellor Merkel and held June 7-8 in Germany, will address the topic of antibiotic resistance. At the beginning of 2014, Sanofi and the Fraunhofer Society established a Natural Product Center of Excellence where scientists from Sanofi and Fraunhofer work to identify novel active compounds to accelerate the discovery and development of new antibiotics.
Following the antibiotics research discussion, Chancellor Merkel and Dr. Brandicourt officially inaugurated a new, high-tech manufacturing facility that is expected to supply Sanofi's new insulin to patients throughout the world. This is one of the most cutting-edge facilities for large volume manufacturing of sterile biologics and incorporates the most modern technology enabling Sanofi to achieve the highest sterility standards in the industry.
"Sanofi is very proud that Chancellor Merkel visited our Frankfurt site, which is Sanofi's largest, integrated site," said Dr. Olivier Brandicourt, Chief Executive Officer, Sanofi. "The Chancellor interacted with research leaders from Sanofi and the Fraunhofer Society to discuss ideas for fueling additional antibiotics research and inaugurated Sanofi's new, high-tech manufacturing facility, which is Sanofi's global production facility for its new insulin therapy for people with diabetes."
Sanofi has invested more than €1 billion in high-technology at Frankfurt-Höchst within the past ten years. At the end of 2014, Sanofi announced further investments of €200 million and, as part of that, created 500 new jobs within the last six months focused on expanding Sanofi's biologics manufacturing capacity. In 2015, Sanofi intends to invest another €100 million to further enhance its high technology production capabilities. Sanofi's presence in Frankfurt includes research and development, biotechnology, production and worldwide distribution of pharmaceutical products, as well as development and production of medical devices.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 30, 2015 15:42:31 GMT -5
They make insulin man. The only thing that makes Afrezza Afrezza is some FDKP and RHI. The finishing lines are what limits capacity.
If anything, this plant will produce the raw material for Afrezza. I wouldn't read into it anymore than that and I definitely wouldn't get all pumped up over it.
|
|
|
|
Post by robsacher on May 30, 2015 16:53:37 GMT -5
I'm still waiting for Obama to show up in Danbury. It could happen… |
|
|
|
Post by notamnkdmillionaire on May 30, 2015 18:46:49 GMT -5
We don't know it's for Afrezza. In fact it would make no sense at this point. Afrezza not yet approved in EU - and that is something like a year long process. Now if tomorrow there was a PR that Sanofi had filed, then I could see them starting to get a plant on line. Bingo. People are jumping to conclusions with no facts to back them up. Could the plant be used? Sure but there is no evidence to support it at this time. But why should it matter when a buy out is going to happen on Monday? Which Monday, no one knows but because so many, especially on Yahoo, have predicted it every other week for a year, it's bound to happen. Fo sho! |
|
|
|
Post by suebeeee1 on May 30, 2015 23:11:30 GMT -5
While Afrezza may go, I can't imagine Sanofi buying all of MNKD. Or MNKD selling all of its Technospere possibilities to Sanofi. The chatter on Yahoo is just chatter. People trying to create rummors to drive up the stock. And as you can see, chatter of a buyout has done nothing to propel the stock anywhere. Obviously, no one takes these predictions seriously.
|
|
